Skip to main content

Albert Baldwin, PhD, is a UNC Lineberger Comprehensive Cancer Center member focusing on the regulation and biological functions of the transcription factor NF-kappaB and on the role of NF-kappaB in disease, with a particular emphasis on cancer and cancer therapy.

Kenan Distinguished Professor
UNC-Chapel Hill
Cancer Cell Biology

Area of Interest

My interest is in dysregulated signal transduction associated with cancer. Our work is largely focused on the IKK/NF-kappaB pathway, which occurs in a variety of cancers. We were the first to show that NF-kB is activated downstream of oncogenic Ras mutations and that blocking NF-kB strongly reduces the oncogenic nature of Ras. We are currently studying an IKK-related kinase, TBK1, and its oncogenic role downstream of Ras mutations, focused on pancreatic cancer. We have found that EZH2 interacts with NF-kappaB to drive cancer-associated phenotypes in breast cancer. We collaborate with numerous investigators related to NF-kappaB signaling in cancer.

Awards and Honors

  • Hyman L. Battle Distinguished Cancer Research Award, 2022
  • NCI Outstanding Investigator Award, 2016
  • NF-kB and control of cell growth and suppression of differentiation
  • Role of oncoprotein Bcl-3 in cell growth and oncogenesis
  • Oncoprotein signaling and NF-kB: Ras- and BCR-ABL-induced pathways and NF-kB
  • NF-kB and suppression of apoptosis: new therapeutic approaches for cancer therapy
  • NF-kB and chromatin: novel findings regarding the involvement of IKK in controlling chromatin/histone modification

Find publications on PubMed

News and Stories

View all related posts

Al Baldwin